LY.US (LLY.US) insulin receptor agonist initiates phase III clinical trial

The Zhitong Finance App learned that on December 15, the US clinical trial listing website showed that LLY.US (LLY.US) initiated the first phase III clinical trial (ENLIGHTEN-2) of Eloralintide (LY3841136).

This phase III study aimed to evaluate the efficacy and safety of eloralintide (four doses, subcutaneous injection) versus placebo in obese or overweight subjects with type 2 diabetes. The primary end point of the study was a percentage change in body weight compared to baseline at week 64.

Eloralintide is an amylin receptor (AMYR) agonist developed by Eli Lilly that may reduce calorie intake by affecting appetite or increasing satiety.